article thumbnail

DEA Regs Bulk Up with 2014 Anabolic Steroid Control Law Additions

FDA Law Blog: Biosimilars

Because anabolic steroids are also abused to enhance athletic performance and increase muscle strength, Congress has enacted three laws regulating anabolic steroids: the Anabolic Steroid Control Acts of 1990 and 2004, and the Designer Anabolic Steroid Control Act of 2014 (“DASCA”). 50,036 (Aug.

article thumbnail

Scientist who discovered semaglutide to study new obesity drug

Drug Discovery World

Pila Pharma was founded in Malmö, Sweden in 2014 by Dorte Gram, formerly part of the obesity research team at Novo Nordisk. In earlier studies, the company demonstrated good safety and signs of efficacy in regulating type 2 diabetes, as well as a significant reduction in a biomarker that indicates risk of heart failure.

Drugs 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis Chemical Thank You The 103 regulations the EPA is currently working on

Agency IQ

The 103 regulations the EPA is currently working on On July 5, 2024, the EPA published its Spring 2024 Unified Agenda, which reveals what regulations the agency is planning on releasing by the end of the year and beyond.

article thumbnail

Article EMA Thank You What you need to know about the status of the proposed EMA fees regulation

Agency IQ

The adoption of a “fees payable” regulation, Council Regulation (EC) No 297/95 , permitted (and continues to permit) the regulator to assess fees for many of the services it provides to medicines developers. There are other fee-related regulations as well.

article thumbnail

A Look Back as the EU Clinical Trial Regulation Moves Forward

PPD

31, 2022, the EU Clinical Trial Regulation (EU CTR) 536/2014 became applicable, heralding a new era for clinical trials in the European Union (EU). Transitioning to EU CTR requirements for existing studies Under the regulation, clinical trial applications submitted before Jan.

article thumbnail

FDA gives companies leeway to go after misinformation, but not free reign

Agency IQ

While the policy is similar in some respects to one first created by the FDA in 2014, the latest version is considerably more detailed regarding what it will – and won’t – allow companies to do.

FDA 59
article thumbnail

The Moving Regulatory Landscape for Gene Therapy Trials in EU: Part 1

thought leadership

Although this regulation applies to CTAs for gene therapy studies, it does not cover the additional requirement for a Genetically Modified Organism (GMO) application for such studies.